Introduction
Notions of what society deems to be an acceptable testing regime for new chemicals are in a constant state of flux. Until 1999 it was acceptable in the EU to perform tests on guinea pigs in order to determine whether certain cosmetic products were hazardous for human skin (Program (1999) ). After 1999 this was Instead, chemicals need to be classified reliably using information from emerging in-vitro and in-silico assays, supplemented where possible by mathematical 10 models. These new methods are likely to be less accurate than in-vivo tests, but are generally cheaper and less ethically problematic to implement. This presents a problem common across toxicology in general: can we make good predictions about the risks associated with new chemicals without using animals at all? In other words, how best can we assemble uncertain information 15 based on non-animal assays, so as to arrive at optimal ethical testing regimes?
Many important papers have emerged on this topic (Gabbert and Weikard (2010) , Gabbert and van Ierland (2010) , Gabbert and Weikard (2013) ,Jaworska J (2010), Jaworska et al. (2013) , Jaworska et al. (2015) , Norlen H (2014) ).
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Indeed (Gabbert and Weikard (2010) ) develops a theory that determines the optimal exposure level of any particular member of the population to the chemical and uses this theory to solve a decision problem of how to pick which chemical to test for hazard first from some finite set of possible chemicals. (Gabbert and van Ierland (2010) ) develops a framework allowing one to compute the optimal 25 battery of tests to assess a generic toxicological endpoint by means of a cost effectiveness analysis (CEA). By contrast, (Gabbert and Weikard (2013) ) develops a framework in which adaptive cost sensitive Integrated Testing Strategies can be derived by means of a Value of Information technique (VOI). The authors there distinguish between decision problems for competitive businesses 30 and regulators. Furthermore, (Jaworska et al. (2015) ) begins by improving and generalising previous work (Jaworska J (2010) , Jaworska et al. (2013) ) by developing more accurate potency class predictions of skin sensitisation potential of chemicals via theory of Bayesian Networks and then uses these results together with VOI framework to derive Optimal Integrated Testing Strategies for the 35 assessment of chemical hazard of chemicals. Finally, similar to (Gabbert and van Ierland (2010) ) and (Gabbert and Weikard (2013) ), (Norlen H (2014) ) uses CEA in the context of performing a cost effectiveness analysis in the special case of acute oral toxicity.
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However, none of these explicitly accounts for the individual differences between humans both in the exposure (i.e. environmental variability) and in the toxicity corresponding caused by that exposure (i.e. individual variability). To be more specific, only Gabbert and Weikard (2010) introduces a concept of toxicity formally but treats it as constant for all members of the population. Moreover, 45 none of these papers combines these with the financial costs of chemical risk classification in a mathematically rigorous fashion.
Any new testing strategy must be able to deal rationally with contradictory evidence. For example, one in-vitro assay may predict that certain chemical is a skin sensitiser, while another in-silico assay may predict that the same chem-50 ical is actually safe. The classification part of the argument in van der Veen et al. (2014) deals with this problem using a combination of majority voting and Bayesian Statistics. Jaworska J (2010) proposes assembling a Bayesian Network and combines this with the Weight-of-Evidence approach to overcome this issue. Thomas et al. (2012) proposes a strategy of "averaging probabilities", using 55 empirical estimates of precision of each assay and then averaging these out in one "meta-assay". Each of these solutions may be pragmatic and defendable within the authors' given problem, but an over-arching logical framework would be a helpful step in confirming the value and risk associated with the removal of animal tests.
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In what follows we shall propose a mathematical framework which seeks to simultaneously overcome the shortcomings mentioned above. The issues of imprecision, and of environment-and individual-level variability, fall naturally within theories developed for evolutionary ecology (Currey et al. (2007) ). The 65 efficient assimilation of evidence can then be handled by well-developed theories of Markov Decision Processes (Bellman (1957) ).
We finish this chapter by surveying previous work in Toxicology and Medicine that is based on this mathematical theory. To the best of our knowledge very 70 little work in Toxicology uses Markov Decision Processes, to be more precise, these are the works of Chang (2010) and Korthikanti et al. (2010) . Chang (2010) is a rich summary of techniques used in contemporary in house pharmacological research and decision making illustrated with numerous examples. Among a vast range of mathematical and computational techniques used are the Markov
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Decision Processes as applied to the optimal decision making of a pharmaceutical business on whether to proceed from earlier (Phase 1 clinical trial) to later (Phases 2 and 3 of clinical trials) stages. Our work generalises this work in a 4 number of directions. Firstly, the models in Chang (2010) are developed for the sake of a making a commercial business more profitable and do not take 80 into account the regulatory aspect of Toxicology, i.e. the fact that the company may actually incur fines from regulatory bodies and lawsuits from individual consumers in case they exhibit adverse outcomes as a consequence of using the drug. The Markov Decision Process model in this paper takes this into account via the mechanisms of misclassification costs: in case the company declares an 85 unsafe chemical as safe there will be serious consequences. Equally, if the company actually declares a safe chemical as unsafe it will lose money by not selling the safe product in the market for which it possibly had an advantage over its competitors. Thus our work bridges the two worlds: it allows the company to maximise its profits while simultaneously acts in the best interest of the gen- Model model are estimated from historical data and power calculations which, by nature, cannot guarantee precisions of estimates in advance in the case of unknown moments. Another problem with this approach is that there is no guarantee the new chemical will share toxicity thresholds with the previously used chemicals. These issues motivate the truly novel part of the methodological 100 work presented in this paper which is applicable in a general setting not necessarily restricted to Toxicology and Medicine. Namely, the transition probabilities between states of the Markov Decision Process in this paper are based on the idea of integrating evidence from different measurements of the same quantity in a non-contradictory way by using the information on the precision from the 105 instruments/assays used in the process. Knowing the value obtained in a less accurate measurement and its precision we can get a probability distribution on the values more accurate measurement of the same quantity can possibly take.
This simple observation has far reaching consequences; namely since the states When it comes to applications in Medicine the literature is much larger. We discuss in detail a variety of different applications (Fakih (2006) , Kurt et al. 130 (2011), Shechter et al. (2008) , Alagoz et al. (2007) , Alterovitz et al. (2008) , Nunes et al. (2017) and Sloan (2007) ) . As mentioned in the above, the main novelty of this paper, logically consistent aggregation of evidence from different measurements in a non-contradictory way and without a need to resort to empirical estimates still stands. Fakih (2006) are made on the authors' guesses and serve to demonstrate how the optimal policies change subject to variation of these. This is similar to our paper with 185 the difference that we study the sensitivity of optimal policies to monetary costs instead.
In summary, we develop a Markov Decision Process for the assessment of hazard of new chemicals while taking into account the exposure, inter-person variabil-190 ity in toxicity and misclassification costs. The result is optimal cost-effective sequential testing strategies for assessment of risk of chemicals. These so-called "optimal policies" rationally integrate outputs from tests with different costs and precisions. The integrated testing frameworks which emerge achieve the keys aims outlined in Pastoor et al. (2014) , Embry et al. (2014) . 
Theory

Individual-and Population-level Models
Much existing literature in quantitative toxicology seems to ignore, or implicitly to average out, the large differences that may exist between the exposure of individuals to potentially toxic chemicals, and the variable effects of a fixed 200 exposure to these chemicals on these individuals. When the purpose of testing is to identify the risk of rare toxicologically harmful outcomes, it seems mathematically expedient to account for this variability explicitly.
We start by providing an alternative view on exposure. Since we cannot know 205 the exact exposure of every single human to the chemical of interest, the natural way to model it is probabilistically. We shall therefore denote exposure experienced by an individual by a random variable X having some distribution with density function f , say, where f would typically correspond to one of many classical distributions (normal, log-normal, gamma). For illustrative purposes,
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here we will assume f is characterised by a single unknown parameter a * , say.
This could correspond, for example, to the variance of the exposure distribution.
We now turn to modelling the variability in toxicity caused by a given exposure. A typical dose-response curve is sigmoidal: Toxicity is typically small up to some threshold level of exposure, beyond which it increases rapidly with exposure before eventually saturating. This behaviour is efficiently captured by a relationship of the form
where A is the level at which toxicity saturates, x is the exposure and p is a model parameter to be inferred from data. However, due to individual-level 215 variability, it makes sense to model toxicity at a given level of exposure as a random variable, having mean specified by the function g together with some unknown variance to be inferred from data. Rigorously, we shall denote toxicity at a level of exposure X = x by a random variable T x . This random variable will have mean
Similarly to the case of exposure (above), we denote the probability density function h x for the random variable T x as being characterised by a single parameter b * .
For the sake of transparency, in what follows assume A and p are known, and 225 that the unknown parameters are a * (relating to exposure variability) and b * (relating to individual variability in response to exposure). The purpose of any optimal testing regime will be, broadly, to find the most efficient way to estimate ranges for a * and b * so as to determine whether or not a chemical is safe. This purpose will be made more precise below, while the generalisation to wider sets 230 of unknown parameters is left to the Discussion.
Definition of safety
From the point of view of a pharmaceutical company it is impossible to predict whether a particular individual who buys their product will be adversely affected by it. Again, only probabilistic language makes sense: for example a criterion 235 that no more than 1 in 1000000 customers is affected at a level exceeding some defined threshold. Suppose γ represents this threshold of toxicity and let T be the random variable indicating the toxicity experienced by an individual sampled randomly from the population. Rigorously, using the logic and notation introduced for exposure and toxicity above, we will declare our chemical of 240 interest to be safe for human use if and only if
By conditioning on the exposure level and using the generalised law of total probability we obtain:
In other words, the chemical is safe for human use if and only if:
The important mathematical step here it that calculating the probability a 245 chemical is safe is reduced to finding the value of a well defined (but unknown) double integral i.e. to evaluating a (possibly complicated) function of a * and b * alone. Thus (4) can be, in general, written as
for some well defined function F . In other words, all we need to deduce whether our chemical is safe or not is knowledge of the parameters a * and b * . Some 250 values of a * and b * correspond to safe chemicals, and some to unsafe chemicals.
It is the job the any testing strategy to identify the real values of a * and b * with sufficient accuracy to determine in which category to place the chemical.
Precision of Measurements
Biological practice shows that one hardly ever obtains the same numerical value 255 upon repeating the same test in the laboratory. Rather, the values observed are random variables. Suppose we have several in-vitro and in-silico tests at our disposal for the assessment of our chemical of interest. Some tests will relate to exposure (i.e. tests attempting to estimate a * ) and some will relate to toxicity (to estimate b * ). All tests will be inaccurate, and we assume that in-vivo tests 260 are the most accurate, followed by in-vitro and in-silico tests respectively.
For mathematical convenience we assume that test outcomes can only take a finite number of values (i.e. that the data are discrete rather than continuous).
This simply allows integrals such as equation 4 to expressed as finite sums, which 265 does not lose generality because the scale of discretisation can be arbitrarily fine.
Specifically, suppose that a series of n independent in-vitro tests for a * has outcomes (random variables) a Because in-vitro tests are likely to be more accurate than in-silico tests, it is reasonable to assume that the random variables a Within the framework developed here, we will show how these costs can, and indeed should, become a part of the development of optimal testing strategies. 
Markov Decision Problems
Our ultimate goal is to find optimal policies for sequential decision making under uncertainty. This is likely to involve the decision about which tests are 12 necessary to depend on the outcomes of earlier tests on the same, or a similar, chemical (Bayer-Zubek (2004)). The optimal testing policy will be the one that Formally speaking, a policy π is simply a function that maps states to actions.
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The value function of a state s under some policy π, denoted V π (s) is formally defined by:
In other words, the values function is the expected sum of future costs/rewards on the assumption that we start at state s. Moreover, we introduce the special state s terminal which is the absorbing state, meaning that when the process 330 13 reaches this state it remains there forever. We demand that
This relation must hold for all policies π simultaneously.
The optimal value function V * of the Markov Decision Process specified above is:
It can be demonstrated that V * satisfies the following equation (Bayer-Zubek (2004)):
all actions a all states s
Again, this relation has to be specified for all states simultaneously. The optimal 340 policy π * is defined state-by-state according to the following relation:
Chemical Risk Classification Problem as a Markov Decision Problem
Recall that, in our general framework, the chemical is safe if and only if:
where a * and b * are the parameters we seek to estimate using various tests.
Recall also that we have n in vitro and m in silico tests for estimating a * . We elaborated on the analogy between problem solved there and our problem in the Introduction. The only fundamental difference is that we have to propose the way of defining the transition probabilities whereas in (Bayer-Zubek (2004)) 355 the authors estimate these are estimated empirically from data.
We have seen in the previous section that a Markov Decision Problem is fully specified by its actions, states and transition probabilities. We first describe the actions of our Markov Decision Problem. These comprise the n + m + p + q 360 available tests and two classification actions ("classify as safe" and "classify as unsafe"). States will represent the complete history of previously observed values upon testing, namely the results of performing various in vitro and/or in silico tests. Indeed, let s stand for the current state of the system. Moreover, assume that the next test to be done is G, say, where G can be any of the 365 tests available to us. Then the system will move to the state s ′ = s ∪ {G = g} where g is one of the possible values of G. The probability of this transition will therefore depend on all the values previously obtained by measurements which is the information kept in s. In other words:
Observe that this ensures Markovian nature of the problem. There will be an 370 initial state which will correspond to the observed values obtained by performing two cheapest in silico tests (or alternatively, expert knowledge), one for each of the parameters. This provides us with a (potentially very wide due to imprecision) initial range of values which a * and b * can take, at a lowest cost possible.
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We note that, because the same test cannot usefully be performed indefinitely, our Markov Decision Problem is acyclic (Bayer-Zubek (2004) which it has been performed) forces transition to s terminal with probability one.
In other words, this state is absorbing, indicating that an evidence-based classification decision has been reached.
All that remains is to introduce the costs of our available classification actions.
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We introduce the quantity M C(ω, ζ) to stand for the misclassification cost for classifying a chemical as ω once its true class is ζ; ω, ζ ∈ {saf e, unsaf e}. Since we do not know the true risk class of the chemical at the time of testing (hence the testing), a natural way of thinking of misclassification cost is to treat it as a random variable. We will say that the cost of classification action ω performed 390 at some state s takes value M C(ω, ζ) with probability P (ζ|s), where this last quantity stands for the chance that the true risk class of the chemical is ζ given that the system is at state s. The expected cost of the action is then:
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Putting all this together, and following Bayer-Zubek (2004), we can deduce that the equation (9) for the optimal value function collapses to
3. Calculation
The preceding work was general and technical, but showed that the problem of finding optimal testing policies for toxicological testing can be mapped to the 400 existing mathematical framework of Markov Decision Processes. To show the value of this result, and to explore its general consequences, it is expedient to proceed via examples.
In these examples it is assumed that the outcome of each test, and the values of the unknown parameters a * and b * , are all integers. This is not a practical limitation, because these integers may refer to measurements at an arbitrarily fine scale; this assumption simply allows methods from discrete (as opposed to continuous) mathematics to be applied and exact results to be computed. As described above, we start by performing the cheapest in silico tests for a * and b *
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(one for each). For sake of simplicity and illustration, we assume the outcomes of these tests are
and that the accuracy of these tests is such that |a s 1 − a * | ≤ 3 and |b
This immediately implies that a * ∈ {3, 4, 5, 6, 7, 8, 9} and b * ∈ {3, 4, 5, 6, 7, 8, 9}.
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Moreover, assume relation (10) defines the following points in the (a * , b * )-plane: (6, 9), (7, 4), (7, 5), (7, 6), (7, 7), (7, 8), (8, 4) , (8, 6), (8, 7), (9.6)} 25 "safe points" of region K are indicated in the Figure 1 below via red points.
Remaining 24 points on the grid represent the "unsafe points". 
Example 1: The case of independent evidence
Consider a simple situation where, on top of the two initial in silico tests, we have one more in vitro test available for each of our parameters a * and b * .
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These will be denoted by a v and b v , respectively. We also have two possible classification actions, namely to classify our chemical as either safe or unsafe.
Recall that the goal is to come up with the optimal sequential testing strategy, that is the one that minimises the expected cost. Evidence is independent in the sense that a * -related tests tell us nothing on b * and vice versa (we shall 430 deal with the case of dependent evidence on the next example). In the spirit of Section 2.6 we introduce states, actions and transition probabilities needed for specifying the corresponding Markov Decision Problem. There will be the initial state corresponding to the observation (15). We will denote this state by {}. Moreover, we will assume in vitro tests are more precise than their in silico 435 counterparts, i.e. that they have a lower absolute measurement error. In order to capture this idea we will assume that:
Using the above one deduces that 2, 3, 4, 5, 6, 7, 8, 9, 10, 11}, b v ∈ {1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11} (17) This together with the idea the fact that a * and b * related tests are independent, gives rise to 11 + 11 + 121 = 143 more states of the system, all listed below:
. . .
Finally, we have the terminal state, s terminal , defined exactly as before.
We now move on to describing the available actions and corresponding transition probabilities. At the initial state {}, there are four actions available: classify as safe, classify as unsafe, do the a v test or do the b v test. This means we must spec-445 ify the following quantities: P ( is saf e|{}, any classif ication action), 2, 3, 4, 5, 6, 7, 8, 9 , 10, 11}.
We start with the first quantity in the above. We have seen that we must have: 4, 5, 6, 7, 8, 9} × {3, 4, 5, 6, 7, 8, 9}, so that 
We now present an argument for defining the quantities of the form 2, 3, 4, 5, 6, 7, 8, 9, 10, 11} . Notice that, due to symmetry, the quantities 2, 3, 4, 5, 6, 7, 8, 9, 10, 11}, can 455 be defined in an analogous way.
For j ∈ {3, 4, 5, 6, 7, 8, 9} define sets T j by
Notice than that a v must belong to at least one of the T ′ j s since the absolute error of the in vitro measurement is 2. With this in mind we define our quantities 460 of interest as follows:
The idea behind (20) is simple. Observe that if we knew the true value of a * were j, say, (16) would immediately tell us that a v ∈ T j (since the absolute error of this measurement is 2). The problem, clearly, is that we do not know the exact value of a * , only that a * is an element of {3, 4, 5, 6, 7, 8, 9}. First, we count all those intervals T j that contain i. Secondly, we scale appropriately to get the normalising constant of the probability density. We then define the probability of interest as a function of the two. For example, notice there is only one suchlike interval that contains value 1, two of them that contain value 2, three of them that contain value 3 and so on. Moreover, let us note that this is only one of the possible ways to define the transition probabilities in a manner consistent with precision of measurements and non-contradictory nature of evidence and is by no means the only one. Thus, the random variable a v |{} has the following 20 distribution: As promised before, the corresponding counterpart for b v test is defined by: 
Now, at the states of the form {a v = i}, i ∈ {1, 2, 3, 4, 5, 6, 7, 8, 9, 
Here #D stands for the number of elements in the set D. Indeed, numerator Yet again, using symmetry and independence, actions in the states of the form {b v = i}, i ∈ {1, . . . 11} are fully specified upon defining:
Finally, it remains to specify the actions and transition probabilities for the states of the form {a
Clearly, there are only two actions available in such states, and these are to classify as safe or unsafe. As before, this boils down to computing
Using the same notation and ideas as before we define these as follows:
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We are now ready to compute the corresponding optimal policies. Because our Markov Decision Problem is acyclic, equation (14) for the optimal value function can be solved in a single sweep through the states. This means we start by 485 computing the optimal value function at the so called "leaf states", that is the states of the form {a v = i, b v = j} and then work our way upwards to the states of the form {a v = i}, {b v = j}(notice we need the information above to compute these). Finally, we finish with the computation of V * ({}) having computed all other necessary quantities along the way. The optimal policy is then read from 490 top down. The actual computations were implemented using MATLAB, code is available upon request.
By manipulating the attribute and misclassification costs we were able to obtain several classes of fundamentally different optimal policies. This clearly demon-
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strates that, even in this apparently simple case, the optimal policy emerges from a complex interplay between the geometry of the feasible region K and the costs present in the problem. Moreover, this shows that simple non-adaptive policies are unlikely to be optimal, that is, having changed your population model and the cost structure you have no reason whatsoever to believe the optimal policy 500 will not change as well. Indeed, one would have to repeat all the steps in the above and compute the optimal policy corresponding to one's favourite interplay between the ingredients. Finally, let us note that this gives the problem a strongly Bayesian flavour. The policies thus obtained, and some motivation for what they emerge, are summarized below. For convenience we introduce the 505 "cost vector" Ω to represent all the costs associated with the problem. Mathematically:
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First we look at the following situation: Ω = (200, 100, 80, 50)
The optimal policy is π * ({}) = "classif y as unsaf e". In plain English means 510 that it is optimal to classify the chemical as unsafe without doing any further test at all. The cost of testing, and of misclassification, mean that the chemical's development should be abandoned.
Secondly, we look at the following cost structure:
515 Ω = (100, 200, 80, 50)
In this case we obtain π * ({}) = "classif y as saf e". In contrast to Case 1, the change in the balance between the consequences of false negatives versus false positives means that we should immediately classify our chemical as safe.
In reality, the cost of testing is likely to be dwarfed by the cost of misclassifica- 
In this case we obtain the following:
, 2, 3, 9, 10, 11}})= "classify as unsafe" 2, 3, 4, 5, 7, 8, 9 , 10, 11} π * ({b v = 5, a v ∈ {5, 6, 7}}) = "classify as safe" 2, 3, 4, 8, 9 , 10, 11}}= "classify as unsafe" π * ({b v = 6, a v ∈ {4, 5, 6, 7, 8}})= "classify as safe" π * ({b v = 6, a v ∈ {1, 2, 3, 9, 10, 11}}= "classify as unsafe" π * ({b v = 7, a v ∈ {5, 6, 7}}) = "classify as safe" 2, 3, 4, 8, 9 , 10, 11}}= "classify as unsafe" 2, 3, 4, 5, 7, 8, 9 , 10, 11}
The above is a mathematical description of the optimal sequential testing policy.
In simple English, the first four lines in the above scheme can be interpreted 
Using the ideas from Section 3.1 we deduce that the corresponding Markov Decision Problem will have a total of 79 states. Detailed description of these and the corresponding transition probabilities can be found in the Appendix.
As in the previous example, it is possible to manipulate attribute and misclas- 
Then the optimal policy is to immediately classify the chemical as safe without doing any test.
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Finally we look at the case capture via the following more realistic cost structure: Ω = (20000, 10000, 80, 50)
The optimal policy turns out to be a complex mixture, interested reader can find the details in the Appendix.
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We finish this section by illustrating another useful feature of our model. Observe that if a v1 = 1 then (24) tells us that a * is an element of {−1, 0, 1, 2, 3}.
However, we actually know for sure that a * is an element of {3, 4, 5, 6, 7, 8, 9}.
Putting these two pieces of information together we deduce that a * = 3, i.e.
we have thus identified a * with absolute certainty. Therefore, common sense 585 tells us that it should not be optimal to do any further a * -related tests after that since we would be simply spending money for learning nothing we already know. Indeed, the above tells us that π * ({a vt1 = 1}) = "classify as unsafe".
This (and other similar situations) are not coincidental. Interested reader can find the formal proof of this fact in the Appendix.
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Discussion and Conclusion
This paper provides a mathematically rigorous framework for the computation of optimal sequential testing strategies for chemical risk classification. Its novelty lies in the fact that it does so by taking into account various important and realistic ingredients. These include population model, errors in laboratory 595 measurements and the corresponding cost structure. Mathematically, the heart of the argument comes from Machine Learning, more specifically the rich theory of Markov Decision Problems. Optimal Sequential Policies were computed in two simple but highly illustrative and easily generalisable examples, namely tests that are independent and those whose outcomes are deeply correlated by 600 the common truth they are revealing with possibly different precision. Indeed, in case of more parameters the corresponding Markov Decision Problem shall simply have more states, all other aspects will be identical.
The key take-home message for toxicological testing is that it is possible, and 605 indeed necessary, to search for optimal testing strategies. Markov Decision
Problems provide a mathematical framework with which to achieve this. We show that the strategies which emerge must explicitly take into account the costs both of testing and of misclassification. Moreover, the optimal testing policies are typically adaptive, where the outcome of any given test influences 610 the decision as to which test (or classification) to apply next. This may be interpreted as a mathematical avocation of the recent interest in adaptive testing strategies from both industry and regulatory bodies.
